Cargando…
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future
Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by complement‐mediated intravascular haemolysis, severe thrombophilia and bone marrow failure. While for patients with bone marrow failure the treatment follows that of immune‐mediated aplastic anaemia, that of classic, haemolytic PNH is ba...
Autores principales: | Risitano, Antonio Maria, Peffault de Latour, Régis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291300/ https://www.ncbi.nlm.nih.gov/pubmed/34355382 http://dx.doi.org/10.1111/bjh.17753 |
Ejemplares similares
-
Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022) -
Paroxysmal nocturnal haemoglobinuria and diabetes mellitus.
por: Andrews, W. J., et al.
Publicado: (1990) -
Coombs-positive Paroxysmal Nocturnal Haemoglobinuria
por: Kalam, Sabrina, et al.
Publicado: (2020) -
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
por: Peffault de Latour, Régis, et al.
Publicado: (2020) -
Paroxysmal Nocturnal Haemoglobinuria: Clinical-Pathological Conference
por: Hewer, T. F.
Publicado: (1963)